Cartesian Therapeutics Grants Inducement Awards to New Employees

On January 2, 2026, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a biotechnology company focused on cell therapy for autoimmune diseases, announced the granting of inducement awards to two new employees. The company issued options to purchase a total of 7,350 shares of its common stock at an exercise price of $6.76, which corresponds to the closing trading price on the Nasdaq Global Market on the date of the grant. These options were granted under the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and received approval from the board of directors.

The Globe and Mail (Toronto)

The stock options vest at a rate of 25% on January 2, 2027, followed by thirty-six equal monthly installments, leading to full vesting by January 2, 2030. The options carry a ten-year term and were granted in accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, which allows for such inducements as a material factor in the employees' decision to join the company.

The Globe and Mail (Toronto)

Cartesian Therapeutics is recognized for its innovative approach to treating autoimmune diseases through cell therapy. The company’s leading asset, Descartes-08, is currently in Phase 3 clinical development targeting patients with generalized myasthenia gravis. Additionally, Cartesian Therapeutics plans to initiate a Phase 2 trial for myositis, further expanding its research and development efforts in the field.

The Globe and Mail (Toronto)

In its announcement, Cartesian Therapeutics emphasized the strategic importance of attracting talent through inducement awards, which are designed to enhance the company's workforce as it advances its clinical programs. The company has not provided specific comments from executives regarding the new hires or the implications of these awards on its future operations.

The Globe and Mail (Toronto)

While the announcement primarily focuses on the inducement awards, there may be concerns regarding the broader implications of such incentives in the biotechnology sector. Critics often argue that inducement awards can lead to inflated compensation packages that do not necessarily correlate with company performance, potentially impacting shareholder value.

The Globe and Mail (Toronto)

As Cartesian Therapeutics continues to develop its clinical assets, the company is expected to provide updates on its trials and any further employment initiatives that may arise as part of its growth strategy. The success of Descartes-08 and other pipeline candidates will be closely monitored by investors and industry analysts alike.

The Globe and Mail (Toronto)

• “The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors.” — Cartesian Therapeutics

The Globe and Mail (Toronto)

• “About Cartesian Therapeutics Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases.” — Cartesian Therapeutics

The Globe and Mail (Toronto)